Trinity Biotech stock gained 21.32 percent on October 5, 2026

Published on 10/07/2026 at 03:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Trinity Biotech stock gained 21.32 percent on October 5, 2026, while shareholders approved all AGM resolutions. Fiscal 2025 revenue fell to USD 43.785 million.

TRIB, US8964385046, Illustration mit AI erstellt.

Trinity Biotech stock (ISIN US8964385046) closed at USD 7.00 on October 5, 2026, gaining 21.32 percent during the session. The move came as StockTitan reported on October 5, 2026, that shareholders had approved every resolution at the September 30 annual general meeting.

AGM resolutions win 95 percent support

Each resolution received at least 95 percent of votes cast, according to StockTitan. The meeting reappointed Grant Thornton as statutory auditor and reappointed Dr Andrew Omidvar as a director, giving the latest corporate update a governance focus rather than a new operating forecast.

The vote is relevant because Trinity Biotech is executing a broader transformation across diagnostics, diabetes management and newer technology initiatives. Its investor-relations page describes products covering infectious-disease testing and haemoglobin A1c, alongside wearable biosensors and services sold through direct and distributor channels in more than 100 countries, according to Trinity Biotech.

Sharp session gain meets a wide range

The October 5 close of USD 7.00 matched the session high of USD 7.00, while the low was USD 6.11. The stock therefore covered USD 0.89 between the session low and high, a material range for a low-priced Nasdaq security.

The 52-week range extended from USD 5.01 to USD 52.50, according to Simply Wall St. That spread places the October 5 close USD 1.99 above the yearly low and USD 45.50 below the yearly high, underscoring the stock's volatility.

Revenue decline remains the operating test

Historical fiscal 2025 revenue was USD 43.785 million, down 28.87 percent from USD 61.555 million in fiscal 2024, while net loss reached USD 37.376 million, according to Reuters. The comparison shows why the market response to corporate updates remains tied to execution and financing capacity rather than governance alone.

TRIB closes at USD 7.00

Trinity Biotech closed at USD 7.00 on Nasdaq on October 5, 2026, with a 21.32 percent daily gain. The company had a market capitalization of USD 4.6 million on October 6, 2026, according to Benzinga.